10-K: Invivyd's 2025 Annual Report: PEMGARDA Sales Up, VYD2311 Advances, Going Concern Doubt Persists

Invivyd, Inc. reports increased PEMGARDA sales and significant clinical progress for VYD2311 in 2025, yet faces substantial doubt about its ability to continue as a going concern due to recurring losses.

Summary

• Invivyd, Inc. is a biopharmaceutical company focused on monoclonal antibody (mAb) therapies for serious viral infectious diseases, starting with COVID-19 and expanding into RSV and measles.
• PEMGARDA (pemivibart), the first mAb to receive regulatory authorization, obtained Emergency Use Authorization (EUA) from the U.S. FDA on March 22, 2024, for pre-exposure prophylaxis of COVID-19 in immunocompromised adults and adolescents.
• VYD2311, a next-generation mAb candidate for COVID-19, was nominated in January 2024 and showed positive Phase 1/2 clinical data for safety and pharmacokinetics in June 2025.
• The FDA aligned with Invivyd in August 2025 on a rapid pathway to potential Biologics License Application (BLA) approval for VYD2311 for COVID-19 prevention, and cleared its Investigational New Drug (IND) application in October 2025.
• The REVOLUTION clinical program for VYD2311 includes the Phase 3 DECLARATION trial, initiated in December 2025 with top-line data anticipated in mid-2026, and the LIBERTY trial, aligned with the FDA in February 2026.
• VYD2311 received Fast Track designation from the FDA for COVID-19 prevention in individuals with underlying risk factors for severe disease.
• Invivyd formed the SPEAR (Spike Protein Elimination and Recovery) Study Group in July 2025 to guide clinical trials for Long COVID and Post-Vaccination Syndrome (PVS) using next-generation antibodies like VYD2311.
• The company announced the selection of VBY329, an RSV mAb candidate, in November 2025, expecting to advance it toward IND readiness in the second half of 2026.
• Invivyd is also targeting identification of a preclinical mAb candidate for measles treatment and prevention in the first half of 2026.
• Net product revenue increased to $53.4 million in 2025 from $25.4 million in 2024, primarily due to increased PEMGARDA sales.
• Net loss for 2025 was $52.5 million, a significant improvement from $169.9 million in 2024.
• As of December 31, 2025, cash and cash equivalents stood at $226.7 million, up from $69.3 million at the end of 2024.
• The company's accumulated deficit reached $954.5 million as of December 31, 2025.
• Invivyd relies on WuXi Biologics as its sole contract manufacturer for COVID-19 product candidates and has long-term master services agreements in place.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern beyond one year from the issuance date of the consolidated financial statements, excluding future revenues or external financing.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While there are significant positive developments in product pipeline and revenue growth, the persistent 'going concern' doubt and reliance on a single authorized product temper the overall sentiment.

Positives

• PEMGARDA received Emergency Use Authorization (EUA) from the U.S. FDA in March 2024, enabling commercialization for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals.
• VYD2311, a next-generation mAb candidate for COVID-19, demonstrated positive full Phase 1/2 clinical data for both safety and pharmacokinetics in June 2025.
• The FDA aligned with Invivyd in August 2025 on a rapid pathway to potential Biologics License Application (BLA) approval for VYD2311 for COVID-19 prevention.
• The FDA cleared the Investigational New Drug (IND) application for VYD2311 in October 2025 and provided feedback to advance the REVOLUTION clinical program.
• The Phase 3 DECLARATION clinical trial for VYD2311 was initiated in December 2025, with top-line data anticipated in mid-2026.
• VYD2311 received Fast Track designation from the FDA, which is designed to facilitate development and expedite regulatory review.
• The SPEAR Study Group was formed in July 2025 to explore mAb therapy for Long COVID and Post-Vaccination Syndrome (PVS).
• Invivyd is expanding its pipeline beyond COVID-19, with the selection of VBY329 as an RSV mAb candidate in November 2025 and targeting a preclinical measles mAb candidate in H1 2026.
• Net product revenue increased by $28.0 million to $53.4 million in 2025, driven by PEMGARDA sales.
• Net loss significantly decreased to $52.5 million in 2025 from $169.9 million in 2024.
• Cash and cash equivalents increased to $226.7 million as of December 31, 2025, providing a stronger liquidity position compared to the previous year.

Negatives

• Invivyd has incurred significant losses since its inception, with an accumulated deficit of $954.5 million as of December 31, 2025.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern beyond one year from the issuance of the consolidated financial statements.
• Invivyd is highly dependent on the commercial success of PEMGARDA, its only authorized product, until other candidates are approved and commercialized.
• The FDA declined Invivyd's request in February 2025 to expand the existing EUA for PEMGARDA to cover treatment of mild-to-moderate COVID-19.
• The EUA for PEMGARDA is temporary and subject to termination or revocation if the public health emergency declaration ends or if variants with reduced susceptibility become dominant.
• Reliance on a single contract manufacturer (WuXi Biologics) for COVID-19 product candidates poses manufacturing and supply chain risks.
• The company has not yet satisfied certain financial covenants and conditions for drawing down the $30 million Term Facility as of December 31, 2025.
• Publicly available neutralization data from third-party labs, even if contested or inconsistent with internal data, can negatively impact regulatory authorization and market acceptance, as seen in October 2024 with PEMGARDA.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern due to recurring losses and the need for additional funding.
• High dependence on the commercial success of PEMGARDA, with no other products currently approved or authorized for sale.
• Newly emerging and future SARS-CoV-2 variants could reduce the activity and effectiveness of mAbs, adversely affecting clinical trials and commercialization.
• Uncertainties exist regarding the development, market acceptance, and reimbursement of COVID-19 product candidates due to the disease's novel and evolving nature.
• The EUA for PEMGARDA is temporary and could be terminated or revoked, requiring pursuit of lengthy and unpredictable traditional regulatory approval processes.
• Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials, leading to potential failures or delays.
• Lack of awareness or negative public opinion of mAb therapies and increased regulatory scrutiny may adversely impact development or commercial success.
• Delays or difficulties in patient enrollment and/or retention in clinical trials could delay or prevent regulatory authorizations or approvals.
• Inability to successfully build a pipeline of additional product candidates through internal efforts or partnerships.
• Monoclonal antibody therapies are complex and difficult to manufacture, and reliance on a single contract manufacturer (WuXi Biologics) creates supply chain risks.
• Potential manufacturing problems, inability to access desired future manufacturing capacity, or raw material shortages could delay development or commercialization.
• If the FDA revokes or terminates the EUA for PEMGARDA, commercial distribution would cease immediately without traditional FDA approval.
• Product candidates may fail to achieve market acceptance by physicians, patients, and third-party payors due to product profile, reimbursement dynamics, or other reasons.
• Inability to continue building and maintaining sales, marketing, and distribution capabilities for PEMGARDA or future authorized/approved product candidates.
• Affected patient populations for product candidates may be smaller than projected, impacting addressable markets.
• Significant competition from vaccines, antiviral agents, and other therapeutics for COVID-19, RSV, and measles.
• Inability to obtain, maintain, and enforce patent protection for product candidates, or if the scope of protection is insufficient, competitors could commercialize similar products.
• Risk of third parties initiating legal proceedings alleging infringement, misappropriation, or violation of intellectual property rights.
• Volatility in the trading price of common stock, potentially leading to substantial losses for purchasers.
• No assurance of continued compliance with Nasdaq listing standards, risking delisting.
• Provisions in corporate charter documents and Delaware law may prevent or frustrate attempts by stockholders to change management or acquire a controlling interest.
• Ability to use net operating losses to offset future taxable income may be subject to limitations.
• Exposure to computer system failures, cyberattacks, or deficiencies in cybersecurity of Invivyd or its third-party partners.
• Failure to comply with various privacy and data security laws, rules, regulations, policies, industry standards, and contractual obligations.
• Potential liability and serious consequences for violations of the FCPA and similar anti-bribery and anti-corruption laws.
• Disruptions at the FDA, SEC, and other government agencies due to funding shortages or global health concerns could hinder regulatory processes.
• Unfavorable global economic conditions and geopolitical events, including trade tensions, could adversely affect business, clinical trials, and manufacturing activities.

Future Outlook

Invivyd anticipates continued significant expenses and operating losses as it advances the REVOLUTION clinical program for VYD2311, pursues regulatory approval for product candidates, and expands its pipeline into RSV and measles. The company expects to require additional funding through various sources to support ongoing operations and growth, with top-line data for the DECLARATION trial of VYD2311 expected in mid-2026 and VBY329 (RSV) advancing toward IND readiness in H2 2026. Identification of a preclinical measles mAb candidate is targeted for H1 2026. The company aims to establish streamlined development pathways for new SARS-CoV-2 mAbs and continues to evaluate manufacturing capacity to meet future demand.

Management Comments

• Invivyd is devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2 and expanding into other high-need indications like RSV and measles.
• PEMGARDA was designed to exert continuous pharmaceutical activity in the face of viral evolution.
• Combating COVID-19 will require for years to come a variety of prevention and treatment options with demonstrated efficacy and safety, particularly for immunocompromised individuals.
• VYD2311's pharmacokinetic profile and antiviral potency may offer the ability to deliver clinically meaningful titer levels through more healthcare systemand patient-friendly means such as IM administration.
• The company aims to develop mAbs that could be used in prevention or treatment of serious viral infectious diseases by leveraging capabilities developed over five years in the COVID-19 space.
• Invivyd expects to require additional funding to achieve its business objectives and will finance operations through a combination of equity offerings, grants, debt, or collaborations.

Industry Context

StockSavvy.ai notes that Invivyd operates in the highly competitive biopharmaceutical industry, characterized by rapid technological evolution and intense competition from major pharmaceutical and biotechnology companies such as AstraZeneca, Roche, Merck, Pfizer, Gilead, GSK, and Sanofi. The company's focus on monoclonal antibodies for infectious diseases, particularly COVID-19, places it in a dynamic market where viral evolution necessitates continuous product innovation. While PEMGARDA holds a unique position as the only currently authorized mAb for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients, the market is subject to the emergence of new variants and the development of alternative therapies, including vaccines and antivirals. The expansion into RSV and measles positions Invivyd to address other high-need infectious diseases, diversifying its pipeline beyond COVID-19, which is a strategic move given the evolving nature of the pandemic into an endemic disease.

Comparison to Industry Standards

• PEMGARDA is currently the only monoclonal antibody authorized by the FDA for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients, distinguishing it from previously authorized mAbs (e.g., tixagevimab/cilgavimab, casirivimab/imdevimab, bamlanivimab/etesevimab, sotrovimab, bebtelovimab) that lost activity against emerging SARS-CoV-2 variants and are no longer authorized for prevention or treatment in the U.S.
• VYD2311's development pathway, including FDA alignment on a single, randomized, placebo-controlled trial for BLA submission and Fast Track designation, suggests a potentially expedited regulatory path compared to traditional drug development, aligning with industry efforts to accelerate therapies for serious unmet medical needs.
• In the RSV prevention market, current options include protein-based vaccines from Pfizer and GSK, an mRNA vaccine from Moderna, and mAbs like Beyfortus (nirsevimab) from AstraZeneca and Sanofi, and Enflonsia (clesrovimab) from Merck. Invivyd's VBY329 aims to be a 'best-in-class' mAb, indicating an ambition to surpass existing offerings in efficacy or safety.
• For measles prevention, existing options are limited to MMR vaccines from Merck and GSK, with no current measles mAb products authorized or approved, presenting a significant unmet need that Invivyd is targeting.

Management Changes

Corporate Governance

Legal Proceedings

• As of December 31, 2025, Invivyd was not a party to any material legal proceedings.
• A securities class action lawsuit, captioned Brill v. Invivyd, Inc., et. al., Case No. 1:23-CV-10254-LTS, filed on January 31, 2023, in the U.S. District Court for the District of Massachusetts, was dismissed with prejudice in September 2024.

Related Party Transactions

• As of December 31, 2025, $0.7 million was due to Adimab, a beneficial owner of more than 5% of Invivyd's common stock, under various agreements (Assignment, Collaboration, Platform Transfer, DNA Sequencing Services, LCMS Services).
• Under the Adimab Assignment Agreement, Invivyd is obligated to pay Adimab up to $24.6 million in development and regulatory milestones, of which $11.1 million has been paid as of December 31, 2025. Mid-single-digit percentage royalties on net sales are also due.
• Under the Adimab Collaboration Agreement, Invivyd pays a quarterly fee ($0.6 million effective January 2024) for exclusivity and is obligated to pay up to $18.0 million in development and regulatory milestones per product, plus mid-single-digit percentage royalties on net sales.
• Under the Adimab Platform Transfer Agreement, Invivyd pays an annual fee (single-digit millions through June 2027) for platform improvements and is obligated to pay up to $9.5 million in development and regulatory milestones per product, plus low single-digit percentage royalties on net sales.
• Invivyd recognized $2.1 million in royalties to Adimab as cost of product revenue in 2025 and $1.0 million in 2024 under the Adimab Assignment Agreement.
• Invivyd recognized $2.4 million of research and development expense related to the quarterly fee under the Adimab Collaboration Agreement in both 2025 and 2024.
• Invivyd recognized $2.0 million of research and development expense related to the annual fee under the Adimab Platform Transfer Agreement in both 2025 and 2024.
• Tamsin Berry, a member of Invivyd's board of directors, is a Limited Partner of Population Health Partners, L.P. (PHP). Invivyd entered into a Master Services Agreement with PHP in November 2022, which was terminated in July 2024. Invivyd paid PHP a cash fee of $0.5 million per month for six months ($3.0 million aggregate) and issued a warrant to purchase 6,824,712 shares of common stock, which had not vested as of December 31, 2025.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings, volatility in stock price, and uncertainty regarding the company's 'going concern' status. However, clinical progress and revenue growth could positively impact long-term value.
• Employees: Continued employment and potential for equity-based compensation, but also subject to the company's financial stability and need for additional funding. Management changes and new inducement plans aim to attract and retain talent.
• Customers (Healthcare Providers, Patients): Access to PEMGARDA for COVID-19 prevention in immunocompromised individuals, and potential future access to VYD2311 and other mAb therapies for infectious diseases. Regulatory decisions and product effectiveness against evolving variants are key.
• Suppliers/Contract Manufacturers (e.g., WuXi Biologics, Adimab): Continued business relationships and potential for milestone/royalty payments, but also subject to contract terms, regulatory changes (e.g., BIOSECURE Act), and Invivyd's financial health.
• Creditors (e.g., Silicon Valley Bank): Obligations under the Term Facility are secured by company assets, but the inability to draw down funds due to unmet covenants highlights credit risk.

Next Steps

• Advance VYD2311 through clinical development, including the REVOLUTION clinical program (DECLARATION and LIBERTY trials).
• Anticipate top-line data for the Phase 3 DECLARATION clinical trial for VYD2311 in mid-2026.
• Advance VBY329 (RSV mAb candidate) toward IND readiness in the second half of 2026.
• Target identification of a preclinical mAb candidate for treatment and prevention of measles in the first half of 2026.
• Continue to commercialize PEMGARDA in the U.S. and potentially expand its market reach.
• Seek additional funding through equity offerings, grants, debt financings, or collaborations to support ongoing operations and growth strategy.
• Monitor SARS-CoV-2 variant evolution and periodically introduce new mAb candidates as needed.
• Evaluate access to manufacturing capacity at WuXi Biologics and other CDMOs to meet potential future demand.

Key Dates

Recommendation

Invivyd presents a mixed financial and operational picture. While the company has achieved significant milestones, including the EUA for PEMGARDA and promising clinical progress for VYD2311, the 'going concern' doubt and substantial accumulated deficit are major concerns. The increased revenue from PEMGARDA sales and successful capital raises in 2025 provide some liquidity, but the long and expensive path to full regulatory approval and commercialization for its pipeline candidates, coupled with intense competition and the evolving nature of viral threats, creates considerable uncertainty. A 'hold' recommendation is appropriate as investors should monitor the company's ability to secure additional funding, meet debt covenants, and successfully advance VYD2311 through pivotal trials and BLA submission, which are critical for long-term viability and profitability.

Keywords

Biopharmaceutical, Monoclonal Antibody, COVID-19, PEMGARDA, VYD2311, RSV, Measles, Emergency Use Authorization, FDA, Clinical Trials, Drug Development, Biologics License Application, Immunocompromised, Infectious Diseases, WuXi Biologics, Adimab, Going Concern, Capital Raise, Nasdaq, Intellectual Property